XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Net sales $ 610,820 $ 676,844
Cost of goods sold 284,854 314,427
Gross profit 325,966 362,417
Selling, general and administrative expense 214,883 225,553
Research and Development Expense 66,375 74,951
Segment profit (loss) 44,708 61,913
Interest expense 12,277 12,337
Foreign exchange (gains) losses, net (1,954) (2,347)
Marketable Securities, Unrealized (Gain) Loss (422,177) 17,525
Other Nonoperating Income (Expense) 34,516 50,431
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 491,078 84,829
(Provision) benefit for income taxes (107,162) (15,867)
Net income attributable to Bio-Rad $ 383,916 $ 68,962
Basic earnings per share:    
Net income per share basic attributable to Bio-Rad $ 13.46 $ 2.33
Weighted average common shares - basic 28,518 29,596
Diluted earnings per share:    
Net income per share diluted attributable to Bio-Rad $ 13.45 $ 2.32
Weighted average common shares - diluted 28,537 29,747